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Abstract 
Ul cells, a suhclone of U937 cells chronically infected with human immunodeficiency virus type 1 (HIV-l), produced HIV-l only in the presence 
of inducers such as 12-0-tetradecanoxylphorbol 13-acetate (TPA) or tumor necrosis factor (TNF)-a. The expression of HIV-antigen on Ul cells 
induced by TPA or TNF-a was found to be prevented by sodium 5,6+enzylidene+ascorbate (SBA) in a concentration-dependent manner. Treatment 
of Ul cells with SBA in the presence of inducers resulted in cell death with cell shrinkage, chromatin condensation and DNA fragmentation into 
nucleosomal oligomers, characteristics of apoptosis. In contrast, SBA had scarcely any apoptotic effect on Ul cells in the absence of inducers. SBA 
did not also induce apoptosis in parental U937 cells in the presence or absence of inducers. These results suggest that HIV-replicating Ul cells 
selectively undergo apoptosis on treatment with SBA. 
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1. Introduction 
Various benzaldehyde derivatives, such as SPA, 4,6- 
benzylidene-a-D-glucose (BG) and /%cyclodextrin ben- 
zaldehyde inclusion compound (CDBA) are known to be 
antitumor drugs [l-8]. Especially, SBA has been shown 
to have antitumor activity not only on chemically-in- 
duced rat tumors but also on inoperable human tumors 
of the ovary, stomach, pancreas, uterus, bile duct and 
lung [7,8]. We previously showed that SBA had no ap- 
parent immuno-potentiation activity such as for stimu- 
lating the productions of cytokines, TNF and inter- 
leukin-1 and -2 in vitro or in vivo [7,8]. Furthermore, we 
recently found that death of tumor cells treated with SBA 
was due to direct induction of apoptosis [9]. 
disappearance of cell surface microvilli [ 10,121. Further- 
more, the internucleosomal cleavage of chromosomal 
DNA is the biochemical characteristic most commonly 
associated with apoptosis [I I, 131. The biological signifi- 
cance of apoptosis stems from its active cell-elimination 
mechanism in response to wide variety of signals, includ- 
ing hormones, chemotherapeutic agents and ionizing 
radiation, and its control functions for physiological 
systems, i.e. neural, endocrine and immune systems. 
Apoptosis is a process of physiological and pathologi- 
cal cell death that occurs during embryogenesis, thymic 
negative selection, hormone-induced tissue atrophy, nor- 
mal tissue turnover and tumor regression [lo-131. The 
most widely accepted criterion of apoptosis is cell mor- 
phological alterations. It is characterized by cell shrink- 
age, fragmentation and condensation of chromatin and 
The National Cancer Institute/the National Institutes 
of Health has implicated a screening system for discovery 
of new classes of synthetic and natural compounds with 
anti-HIV activity. Apoptosis inducible activity of SBA 
and the possible availability of its derivatives prompted 
us to explore the potential anti-HIV activity of this chem- 
ical class. There is also no information so far about the 
effect of SBA on HIV replication. We, therefore, investi- 
gated the ability of SBA to inhibit HIV-l replication in 
cultured Ul cells infected with HIV-l. We demonstrate 
here that SBA selectively induced apoptotic cell death of 
Ul cells expressing HIV-l in the presence of inducers. 
These findings provide encouragement for its considera- 
tion as a new mechanistic type of anti-HIV drug. 
*Corresponding author. Fax: (81) (3) 3268-3045. 
Abbreviations: SBA, sodium 5,6-benzylidene-L-ascorbate; HIV, human 
immunodeficiency virus; TPA, 12-0-tetradecanoxylphorbol 13-acetate; 
NFKB; nuclear factor kappa B; LTR, long terminal repeat; TNF, tumor 
necrosis factor; PKC, protein kinase C; bp, base pair. 
2. Materials and methods 
2. I. Materials 
SBA, which is a mixture of diastereomers (S/R = l/2) (see Fig. 1 for 
chemical structures) [9], was purchased from ChemiScience Ltd., 
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Tokyo. TPA, 
nant human 
RNase A and proteinase K were from Sigma. Recombi- 
TNF-a more than 99% pure had a specific activity of 
3 x 10’ units/mg protein. DNA size markers of #X174 DNA digests 
with HaeIII were from Toyobo Co. Ltd., Japan. All other reagents were 
of analytical grade. 
2.2. Cell culture and virus 
Human histiocytic lymphoma (U937) cells and a subclone of U937 
cells integrated with two copies of HIV-I, Ul cells, were cultured in 
RPMI-1640 medium supplemented with 10% heat-inactivated FCS, 
penicillin (100 III/ml) and streptomycin (100 &ml) at 37°C in Co2 
incubator. Cell viability was measured as exclusion of 0.2% Trypan blue 
under phase contrast microscopy. The frequency of apoptotic cells was 
counted under light microscopy after staining with erythrocin B. A 
strain of HIV-I, HTLV-IIIB, was used in the anti-HIV assay. The virus 
was prepared from the culture supernatant of Molt-4/HTLV-IIIB cells 
which were persistently infected with HTLV-IIIB [14]. 
2.3. HIV expression 
HIV-expressing cells were determined by using human polyclonal 
anti-HIV-l antibody. Ul or U937 cells were cultured in the presence 
or absence of an inducer for the indicated times and then successively 
treated with human polyclonal anti-HIV-l positive serum and FITC- 
conjugated rabbit anti-human IgG. Numbers of HIV-I antigen positive 
cells were counted in a CytoACE-150 (Japan Spectroscopic Co. Ltd., 
Japan) equipped with a 488 nm Argon laser and 10 mW light output. 
FITC emission signals were collected using the standard filter set and 
amplified logarithmically. Ten-thousand events per sample were col- 
lected, stored and analyzed [15]. 
2.4. DNA fragmentation assay 
Cells were harvested and lysed in lysis buffer (50 mM Tris-HCI (pH 
7.8) 10 mM EDTA, 0.5% w/v sodium N-lauroyl sarcosinate). DNA 
was prepared from the lysates by successive treatments with 0.5 mg/ml 
RNase A for 30 min and 0.5 mg/ml proteinase K for 40 min at 50°C. 
The resultant DNA preparation was subjected to 2% agarose gel elec- 
trophoresis. DNA fragmentation detected by ethidium bromide stain- 
ing was examined in photographs taken under UV-illumination. Per- 
cent fragmentation was determined by densitometric analysis of the 
DNA fragments as described previously [9]. 
3. Results 
HIV replication in Ul cells was detected by the ap- 
pearance of HIV-l antigen on the cell surface. As shown 
in Fig. 2, approximately 25% of the total Ul cells ex- 
pressed HIV-l antigen after 2 days treatment with TPA 
or TNF-a. Interestingly, in both inducers, SBA signifi- 
cantly inhibited the appearance of HIV-l antigen posi- 
ISI [RI 
Fig. 1. Structure formulae of diastereomers of SBA. 
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Fig. 2. Inhibitory effect of SBA on Ul cells expressing HIV-l-specific 
antigen. Ul cells were cultured in the absence (0) or presence of 3 ng/ml 
TPA (0) or 3 ng/ml TNF-a (A) with the indicated concentrations of 
SBA for 2 days. The percentage of HIV-l antigen-positive cells, deter- 
mined as described in section 2, is shown as a function of the SBA 
concentrations. Values are means of three determinations (standard 
errors of the means 5 10%). 
tive cells. The half-maximal effective concentrations 
(EC,,) of TPA and TNF-a were calculated to be 70 and 
40 &ml, respectively. SBA itself did not induce HIV-l 
replication in the absence of inducers. 
We next examined the cytocidal effect of SBA on Ul 
cells. The viability of Ul cells in the presence of TPA or 
TNF-a was decreased ose-dependently by SBA treat- 
ment, but SBA had essentially no effect on Ul cells not 
producing HIV (in the absence of an inducer) (Fig. 3a). 
Interestingly, the percentage decreases of viability (Fig. 
3a) were almost the same as those of HIV-antigen posi- 
tive Ul cells (Fig. 2). The EC,,, values for the cytocidal 
effect of SBA in the presence of TPA and TNF-a were 
60 and 30 pg/ml, respectively. These values were also the 
same as those of suppression of HIV-I antigen produc- 
tion (Fig. 2). On the other hand, SBA had essentially no 
cytocidal effect on noninfected parental U937 cells (Fig. 
4a). Thus the HIV-replicating Ul cells seemed to be 
selectively affected by SBA. 
These findings led us to suppose that SBA might in- 
duce apoptotic cell death of Ul cells expressing HIV- 1. 
To test this possibility, we investigated the effect of SBA 
on cell morphology and DNA fragmentation, which are 
criteria of apoptosis [lo-l 31, of Ul cells in the presence 
of TPA or TNF-a. Light microscopic analysis showed 
that approximately 20% and 10% of Ul cells were 
shrunken after SBA treatment for 2 days in the presence 
of TPA and TNF-a, respectively (Fig. 3b). In these cells, 
chromatin condensation was also observed. In contrast, 
SBA treatment resulted in little apoptotic effect on U937 
cells at concentrations of O-400 PM (Fig. 4b). 
Evidence that SBA induced DNA fragmentation in the 
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nucleus was demonstrated by agarose gel electrophoresis 
(Fig. 5). In SBA-treated Ul cells in the presence of TPA 
or TNF-cx, a substantial amount of DNA was cleaved 
into a ladder of discrete fragments of nucleosomal DNA 
(approximately 180 bp). In contrast, little DNA frag- 
mentation was observed in Ul cells producing HIV-l 
without SBA treatment (treated with TPA or TNF-a 
alone). Moreover, Ul cells treated with SBA alone did 
not show any and DNA fragmentation (Fig. 5) as well 
as morphological alterations (Fig. 3b), characterisatics 
of apoptosis. 
4. Discussion 
Here we report that SBA suppressed HIV-replication 
in cultured Ul cells induced by TPA or TNF-a. SBA was 
found to kill Ul cells in the presence of inducers via 
events characteristic of apoptosis. At concentrations of 
25-200pM of SBA, there was a clear separation between 
its effects on HIV-producing cells and nonproducing U 1 
and parental U937 cells indicating its selective induction 
of apoptosis in HIV-replicating Ul cells. Thus the ob- 
served effect of SBA on HIV-replicating Ul cells is sug- 
gested to be the results of a direct effect in inducing 
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Fig. 3. Induction of apoptosis in Ul cells by SBA. Ul cells were treated 
with SBA in the absence (0) or presence of 3 ng/ml TPA (0) or 3 ng/ml 
TNF-a (A) for 2 days. Cell viability (a) and appearance of apoptotic 
cells (b) were measured as described in section 2. Values are means of 
three determinations (standard errors of the means 5 8%). 
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Fig. 4. Effect of SBA on U937 cell viability and apoptosis. U937 cells 
were treated with SBA in the absence (0) or presence of 3 ng/ml TPA 
(0) or 3 @ml TNF-Q (A) for 2 days. Cell viability (a) and appearance 
of apoptotic cells (b) were measured as described in section 2. Values 
are means of three determinations ( tandard errors of the means c 7%). 
apoptosis not a cytostatic effect. This assumption is sup- 
ported by the observation that the percentage reduction 
of HIV-antigen positive Ul cells by SBA in the presence 
of TPA or TNF a was almost the same as that of appear- 
ance of apoptotic cells. Furthermore, SBA seemed to 
have a selective action on HIV-replicating Ul cells be- 
cause treatment of Ul cells with SBA in the absence of 
inducers resulted in no apoptotic effect. Moreover, even 
in the presence of inducers, SBA had essentially no effect 
on parental U937 cells over the range of concentrations 
tested. These findings are consistent with the hypothesis 
that the anti-HIV activity of SBA in Ul cells is due to 
its selective inducibility of apoptosis to HIV-replicating 
Ul cells. The molecular basis of this selectivity is un- 
known, but may be related to differences in metabolic 
activities and homeostatic mechanisms at the cellular 
level. We are now investigating how SBA selectively in- 
duces apoptosis in HIV-replicating Ul cells. 
It is noteworthy that suppression effect of SBA on 
HIV replication induced by TNF-a was observed at 
lower concentrations of SBA than that by TPA. The 
signal transduction of TPA is known to be mediated by 
protein kinase C (PKC) [16-191. In contrast, activation 
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Fig. 5. DNA fragmentation analysis by agarose gel electrophoresis of 
DNA from SBA-treated Ul cells. Ul cells were treated with the indi- 
cated concentrations of SBA for 2 days in the presence or absence of 
3 ng/ml TPA or 3 ng/ml TNF-a. Number at right of figure represent 
the size of DNA standards in base pairs. 
of NFlcB, which is a transcription factor binding to the 
FCB motif in HIV-long terminal repeat (LTR), by TNF-a: 
can occur independently of PKC [17,18,20]. Although 
the intracellular mediator of TNF-a is not yet ascer- 
tained, production of radical oxigens has been suggested 
to be involved in NFrcB activation [21-231. Since SBA is 
known to be an anti-oxidant [24], treatment of SBA 
might result in inhibition of NFnB activation induced by 
TNF-a in addition to its triggering apoptosis. So the 
combined effect is probably the reason why SBA was 
more suppressive to HIV replication induced by TNF-ol 
than that by TPA. This idea is supported by observations 
that anti-oxodants could suppress HIV-replication 
[25,26]. 
So far a large number of antiretroviral compounds 
have been proven to be effective against HIV infections 
[27]. Inhibition of nucleoside reverse transcriptase such 
as 3’-azido-2’,3’-deoxythymidine (AZT), 2’,3’-dideoxy- 
inosine (dd1) and 2’,3’-dideoxycytidine (ddC) are clini- 
cally available, but their efficacies are limited [28]. Thus 
new types of compounds with anti-HIV activity are re- 
quired. Agents inducing apoptosis such as SBA and its 
derivatives may be new types of anti-HIV drugs. Al- 
though the molecular mechanism of SBA-induced apop- 
tosis still remains to be determined, we anticipate that 
selective induction of apoptosis in HIV-expressing Ul 
cells could lead to new methods of therapy for HIV- 
related dieseases. 
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